Undoubtedly, COVID-19 has changed many aspects of our daily lives, but has it changed the value of your business? Find out how MidCap helps clients evaluate the risks and
opportunities in these uncertain times.
Navigating the Healthcare M&A Process
Built by healthcare operators who have led hospitals, practices, and specialty care businesses. We guide management teams through complex transactions with a practical, informed approach.
Our healthcare group is built around operators and advisors with firsthand experience leading hospitals, physician practices, clinical research organizations, and specialty healthcare services businesses. The team includes former healthcare executives and clinicians who have managed complex care environments, overseen regulatory and reimbursement frameworks, and driven growth across both clinical and administrative functions. Because we have operated inside these organizations, we speak the same language as management teams and understand the realities of delivering care while building enterprise value.
Through diligence across a broad range of healthcare transactions, we maintain a current, operator-level view of what buyers, lenders, and investors expect in today’s market. That perspective allows us to identify issues early, focus on the operational and financial drivers that matter most, and guide clients through complex processes with clarity and confidence.
MidCap Advisors brings a differentiated, operator-driven approach to healthcare M&A. With more than 100 years of combined operating and transactional experience and a senior-led, boutique process, we help healthcare owners navigate complex markets, position value clearly, and achieve the right outcome with confidence.
MidCap brings direct experience buying, operating, and selling healthcare businesses, giving clients a real-world perspective on value drivers, risk, and buyer priorities across the sector.
MidCap pairs Wall Street-level skills with exclusive middle-market focus and a 360-degree, client-centric approach — aligning every decision to the owner’s goals and long-term value creation.
Every engagement is spearheaded by a Partner/Managing Director and supported by a dedicated deal team. We handle diligence and negotiations end-to-end, minimizing executive disruption and moving clients to market quickly and confidently.
Ambulatory Surgery
Cardiology
Dermatology
Gasstroenterology
Hospitalist/Staffing
Neurosurgery
Ophthalmology
Orthopedics
Pain Management
Physical Therapy
Radiology
Urology
Fertility
Women’s health
Contract Research Organisation (CRO)
Just like in your business, our people are what make us great
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
From
MidCap Advisors LLC
675 Third Avenue, 28th Floor New York, NY 10017
Contact
Undoubtedly, COVID-19 has changed many aspects of our daily lives, but has it changed the value of your business? Find out how MidCap helps clients evaluate the risks and
opportunities in these uncertain times.
Learn about MidCap’s Transaction Roadmap – how we work with our clients at all phases of the process, and why the most important step could be the one you take now, even if a potential sale is in the distant future.
Find out how the MidCap team found hidden value and helped agency owners achieve outstanding returns in these unique transactions.
Download our latest analysis on The Impact of Interest Rates and Capital Gains Tax on Net Proceeds for Insurance Agency Owners.
Our Vice President of Healthcare, Our Team, was featured in a Healthcare Business International article that further speculated about Fresenius’ strategy to offload its expansive fertility asset, The Eugin Group, to the M&A market. It is through the courtesy of Healthcare Business International that we can share this information with our audience.
Robert shared insights related to The Eugin Group’s partnerships with prominent IVF clinics across 3 continents, he assessed the overall U.S. M&A market, and he explained the market from an investor’s perspective. Also, with experience as an administrator and CEO of a hospital, Robert observed that even though European hospitals are selling “non-core” fertility assets, U.S. hospitals are not doing the same currently. Robert cited higher concentrations of older patients with critical needs, nurse shortages, and wage demands as possibilities for why hospitals would need liquidity.
MidCap Advisors LLC is pleased to be a sponsor of the 12th Annual Brach Eichler New Jersey Healthcare Market Review (NJHMR) September 28-29 at the Borgata Hotel Casino Spa in Atlantic City, New Jersey. NJHMR provides a unique opportunity to connect with over 200 attendees comprised of hospital and ambulatory surgery centers executives and stakeholders, physicians, practice owners and managers, and healthcare administrators. During the two-day event, industry experts will discuss timely topics and trends in the healthcare and legal space ranging from legislative issues to operating and business strategies for greater profitability. Our own Robert S. Goodman (Bob) will be a panelist for the Friday, September 29th 11:00 a.m. to 12 noon session General Practice Management Panel of Experts: Hot Topics Relevant to Your Practice.
If you are contemplating selling your practice and have an interest in learning more about the M&A market for physician practices and ambulatory care centers in New Jersey, be sure to attend Bob’s panel and meet the MidCap Healthcare team at the conference.
MidCap Advisors’ Vice President of Healthcare Robert S. Goodman offered comment to Inside Reproductive Health regarding investment bank KKR’s move to acquire Fresenius’s Eugin Group. The prospective transaction would make KKR one of the largest players in the global fertility space, following its acquisition of IVIRMA earlier this year.
MidCap Advisors’ Vice President of Healthcare Brijinder S. Minhas was quoted by Inside Reproductive Health following the appointment of new CEOs at both The Fertility Partners and First Fertility.
The Fertility Partners (TFP) announced Derek Larkin as its new CEO on August 16, the same month that Cara Reyman took over as CEO of First Fertility, Larkin’s old post. Reyman was the CEO of a different fertility clinic network, Fertilitas, from July 2022 to July 2023.
Andrew Meikle, founder of TFP, served as the company’s first CEO from September 2019 to August 2023. Meikle will continue to serve as founder and executive chairman as the transition occurs to supporting partner relationships, corporate development and strategic decision-making.
The Fertility Partners, founded in 2019, is a network of fertility practices with 36 clinic locations across North America, including 14 IVF centers. With more than 75 physicians and 1,000 employees, TFP operates in six provinces in Canada.
Larkin’s experience extends beyond his time as CEO of First Fertility from May 2020 to July 2023. He held various leadership positions over a span of 12 years at Boston IVF, including CEO. In his roles at Boston IVF, Larkin demonstrated developed expertise in managing operations and guiding strategic direction, according to TFP.
This background places him in an ideal position to lead TFP and further enhance its offerings to partner clinics, according to TFP.
“My life’s work has been in fertility, striving to improve the patient experience along their journey of family building,” Larkin said in a statement. “I am excited to continue to lead this amazing organization with that purpose.”
“This is a transformational time in our business, and we are very excited to have Derek guide the TFP team as we continue our growth across North America,” Meikle said in a statement. “We have a tremendous alignment of vision and values, and his extensive operational expertise, sector knowledge and leadership will enhance our offering to partner clinics.”
Dr. Brijinder Minhas was a partner and COO at NewLIFE in Florida for 22 years before it was acquired by First Fertility in 2022. MidCap Advisors were investment bankers. After the sale, Minhas joined MidCap as vice president of healthcare.
“It is important that management companies truly understand the nuances of the practice they are dealing with,” Minhas said.
“Having managers and C-suite folks with prior fertility experience, in my opinion, is essential and leads to a much more productive and profitable relationship … The reasons for the shake-up at First Fertility are not known. A good warning for other CEOs: ‘Hire the right team and keep both the practices and private equity bosses happy.’ Ultimately, clinicians want to provide the best patient care, and management partners want to maximize profitability. A good balancing act is required.”
Meikle and Larkin declined to comment on the transition for the purposes of this article.
MidCap Advisors is a New York-based M&A advisory firm providing sophisticated financial advice and M&A transaction services to private companies. MidCap Advisors offers industry-leading analysis that integrates both quantitative and qualitative factors to accurately assess the total value of a transaction, ensuring it meets the client’s definition of success. Over the past 20 years, MidCap has become a recognized leader in insurance M&A and transactional support services. The firm also has extensive M&A expertise in other sectors such as healthcare, manufacturing, business and technology services. The MidCap team’s deep experience as investment bankers has enabled additional focus on due diligence, consulting, and direct investing.
To learn more about MidCap’s healthcare M&A experience, visit Healthcare M&A .
###
